VC-Backed Spark Therapeutics Boosts IPO Target To $157M
Venture capital- and hedge fund-backed Spark Therapeutics Inc., an early stage biotech developing drugs to treat rare blinding conditions, upped its initial public offering target on Wednesday to $157 million, hoping...To view the full article, register now.
Already a subscriber? Click here to view full article